BioDelivery Sciences International Inc. (Nasdaq: BDSI) reported disappointing
results from a Phase 3 study of Clonidine Topical Gel to treat painful
diabetic neuropathy sending the stock price plummeting $3.38 to close at $10.51.
Disappointing study results for BioDelivery Sciences
March 30, 2015 at 17:08 PM EDT